The relationship between glycaemic control and mortality in patients with type 2 diabetes in general practice (ZODIAC-11)
Authors:
- Gijs W LandmanGLGijs W Landman
- Kornelis Jj van HaterenKHKornelis Jj van Hateren
- Nanne KleefstraNKNanne Kleefstra
- Klaas H GroenierKGKlaas H Groenier
- Rijk Ob GansRGRijk Ob Gans
- Henk Jg BiloHBHenk Jg Bilo
- 1 March 2010
- journal article
- research article
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 60 (572) , 172-175
Abstract
The relationship between the degree of glycaemic control and mortality remains an important topic of discussion. This study aimed to investigate this relationship. Prospective cohort study. Primary care. A total of 1145 patients with type 2 diabetes were enrolled in the Zwolle Outpatient Diabetes project Integrating Available Care (ZODIAC) in 1998. Their survival status was recorded in September 2004. Mortality ratios were calculated using standardised mortality ratios (SMRs). Associations between haemoglobin A(1c) (HbA(1c)) levels and mortality were studied with a Cox proportional hazard model. HbA(1c) levels were studied as continuous and as categorical variables. A total of 335 patients died after a median follow-up period of 5.8 years. The SMR (95% confidence interval [CI]) for total mortality was 1.86 (95% CI = 1.66 to 2.06) and 2.24 (95% CI = 1.91 to 2.61) for cardiovascular mortality. For each 1% increase in HbA(1c) there was a 21% increase in the hazard ratio for total mortality. When compared with the target HbA(1c) group (HbA(1c) 6.5-7%), the group with very poor glycaemic control (HbA1c >9%) had a hazard ratio of 2.21 (95% CI = 1.42 to 3.42) for total mortality. The group with normal glycaemic control (HbA(1c) <6.5%) had a hazard ratio of 1.00 (95% CI = 0.46 to 2.19) for total mortality. HbA(1c) level was associated with mortality and this effect seemed largely attributable to patients who were in really poor glycaemic control. The absence of differences in mortality in the groups with lower HbA(1c) levels supports the position that there is no basis for continually decreasing the therapeutic target HbA(1c) level in patients with type 2 diabetes mellitus.Keywords
This publication has 12 references indexed in Scilit:
- Glucose Control and Vascular Complications in Veterans with Type 2 DiabetesNew England Journal of Medicine, 2009
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2008
- Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trialsAmerican Heart Journal, 2006
- Shared care with task delegation to nurses for type 2 diabetes: prospective observational study.2005
- Meta-Analysis: Glycosylated Hemoglobin and Cardiovascular Disease in Diabetes MellitusAnnals of Internal Medicine, 2004
- Molecular Understanding of Hyperglycemia's Adverse Effects for Diabetic ComplicationsJAMA, 2002
- Postchallenge Hyperglycemia and Mortality in a National Sample of U.S. AdultsDiabetes Care, 2001
- Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational studyBMJ, 2000
- Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial InfarctionNew England Journal of Medicine, 1998
- Cause-specific mortality in a population-based study of diabetes.American Journal of Public Health, 1991